These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 32423769)

  • 1. Success of Weekly Adalimumab in Refractory Ocular Inflammatory Disease.
    Lee J; Koreishi AF; Zumpf KB; Minkus CL; Goldstein DA
    Ophthalmology; 2020 Oct; 127(10):1431-1433. PubMed ID: 32423769
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis.
    Correll CK; Bullock DR; Cafferty RM; Vehe RK
    Clin Rheumatol; 2018 Feb; 37(2):549-553. PubMed ID: 29103180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis.
    Skrabl-Baumgartner A; Seidel G; Langner-Wegscheider B; Schlagenhauf A; Jahnel J
    Arch Dis Child; 2019 Mar; 104(3):246-250. PubMed ID: 30026253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uveitis in sporadic Blau syndrome: Long-term follow-up of a refractory case treated successfully with adalimumab.
    Naik AU; Annamalai R; Biswas J
    Indian J Ophthalmol; 2018 Oct; 66(10):1483-1485. PubMed ID: 30249847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Adalimumab on Peripheral Blood Mononuclear Cells in Non-Infectious Uveitis.
    Walscheid K; Weinhage T; Foell D; Heinz C; Kasper M; Heiligenhaus A
    Ocul Immunol Inflamm; 2019; 27(2):330-337. PubMed ID: 29020495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab for the treatment of refractory noninfectious paediatric uveitis.
    Muñoz-Gallego A; Barral E; Enríquez E; Tejada P; Barceló A; de Inocencio J
    Int Ophthalmol; 2017 Jun; 37(3):719-725. PubMed ID: 27432171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effectiveness of adalimumab treatment for non-infectious uveitis.
    Hasegawa E; Takeda A; Yawata N; Sonoda KH
    Immunol Med; 2019 Jun; 42(2):79-83. PubMed ID: 31315546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A three-centre experience with adalimumab for the treatment of non-infectious uveitis.
    Dobner BC; Max R; Becker MD; Heinz C; Veltrup I; Heiligenhaus A; Barisani-Asenbauer T; Mackensen F
    Br J Ophthalmol; 2013 Feb; 97(2):134-8. PubMed ID: 23212204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Efficacy of Biosimilar Switch of Adalimumab for Management of Uveitis.
    Murray GM; Griffith N; Sinnappurajar P; Al Julandani DA; Clarke SLN; Hawley DP; Choi J; Guly CM; Ramanan AV
    Ocul Immunol Inflamm; 2024 May; 32(4):442-446. PubMed ID: 36803373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular disease--a case cohort interventional study.
    Sen ES; Sharma S; Hinchcliffe A; Dick AD; Ramanan AV
    Rheumatology (Oxford); 2012 Dec; 51(12):2199-203. PubMed ID: 22923752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease.
    Martín-Varillas JL; Calvo-Río V; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Garfella MH; Pascual EV; Martínez-Costa L; Sellas-Fernández A; Cordero-Coma M; Díaz-Llopis M; Gallego R; Salom D; Ortego N; García-Serrano JL; Callejas-Rubio JL; Herreras JM; García-Aparicio Á; Maíz O; Blanco A; Torre I; Díaz-Valle D; Pato E; Aurrecoechea E; Caracuel MA; Gamero F; Minguez E; Carrasco-Cubero C; Olive A; Vázquez J; Ruiz-Moreno O; Manero J; Muñoz-Fernández S; Martinez MG; Rubio-Romero E; Toyos-Sáenz de Miera FJ; López Longo FJ; Nolla JM; Revenga M; González-Vela C; Loricera J; Atienza-Mateo B; Demetrio-Pablo R; Hernández JL; González-Gay MA; Blanco R
    Ophthalmology; 2018 Sep; 125(9):1444-1451. PubMed ID: 29602570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients.
    Díaz-Llopis M; Salom D; Garcia-de-Vicuña C; Cordero-Coma M; Ortega G; Ortego N; Suarez-de-Figueroa M; Rio-Pardo MJ; Fernandez-Cid C; Fonollosa A; Blanco R; Garcia-Aparicio AM; Benitez-Del-Castillo JM; Olea JL; Arevalo JF
    Ophthalmology; 2012 Aug; 119(8):1575-81. PubMed ID: 22525047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab for the treatment of refractory active and inactive non-infectious uveitis.
    Lee JT; Yates WB; Rogers S; Wakefield D; McCluskey P; Lim LL
    Br J Ophthalmol; 2018 Dec; 102(12):1672-1678. PubMed ID: 29459430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adalimumab for treatment of severe Behçet's uveitis: a retrospective long-term follow-up study.
    Interlandi E; Leccese P; Olivieri I; Latanza L
    Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S58-62. PubMed ID: 25005224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab for Treatment of Noninfectious Uveitis: Immunogenicity and Clinical Relevance of Measuring Serum Drug Levels and Antidrug Antibodies.
    Cordero-Coma M; Calleja-Antolín S; Garzo-García I; Nuñez-Garnés AM; Álvarez-Castro C; Franco-Benito M; Ruiz de Morales JG
    Ophthalmology; 2016 Dec; 123(12):2618-2625. PubMed ID: 27692527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydrogel eye drops as a non-invasive drug carrier for topical enhanced Adalimumab permeation and highly efficient uveitis treatment.
    Chen Z; Yang M; Wang Q; Bai J; McAlinden C; Skiadaresi E; Zhang J; Pan L; Mei C; Zeng Z; Yu J; Feng Y; Jiang Z; Xu W; Xu H; Ye X; He H; Wang Q; Deng J; Huang J
    Carbohydr Polym; 2021 Feb; 253():117216. PubMed ID: 33278980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term adalimumab treatment of hidradenitis suppurativa: Results and practical insights from a real-life experience.
    Bettoli V; Manfredini M; Calamo G; Forconi R; Bencivelli D; Mantovani L; Pellacani G; Corazza M
    Dermatol Ther; 2018 Nov; 31(6):e12737. PubMed ID: 30295378
    [No Abstract]   [Full Text] [Related]  

  • 18. Infliximab and adalimumab for uveitis.
    Martel JN; Esterberg E; Nagpal A; Acharya NR
    Ocul Immunol Inflamm; 2012 Feb; 20(1):18-26. PubMed ID: 22324897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial.
    Papp K; Thaçi D; Marcoux D; Weibel L; Philipp S; Ghislain PD; Landells I; Hoeger P; Kotkin C; Unnebrink K; Seyger M; Williams D
    Lancet; 2017 Jul; 390(10089):40-49. PubMed ID: 28478975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adalimumab therapy for refractory childhood uveitis.
    Bravo-Ljubetic L; Peralta-Calvo J; Noval S; Pastora-Salvador N; Abelairas-Gómez J; Merino R
    J AAPOS; 2013 Oct; 17(5):456-9. PubMed ID: 24160962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.